Liver X receptor biology and pharmacology: New pathways, challenges and opportunities

Tomas Jakobsson, Eckardt Treuter, Jan Åke Gustafsson, Knut R. Steffensen

Research output: Contribution to journalReview articlepeer-review

235 Scopus citations


Nuclear receptors (NRs) are master regulators of transcriptional programs that integrate the homeostatic control of almost all biological processes. Their direct mode of ligand regulation and genome interaction is at the core of modern pharmacology. The two liver X receptors LXRα and LXRβ are among the emerging newer drug targets within the NR family. LXRs are best known as nuclear oxysterol receptors and physiological regulators of lipid and cholesterol metabolism that also act in an anti-inflammatory way. Because LXRs control diverse pathways in development, reproduction, metabolism, immunity and inflammation, they have potential as therapeutic targets for diseases as diverse as lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases. Recent insights into LXR signaling suggest future targeting strategies aiming at increasing LXR subtype and pathway selectivity. This review discusses the current status of our understanding of LXR biology and pharmacology, with an emphasis on the molecular aspects of LXR signaling that constitute the potential of LXRs as drug targets.

Original languageEnglish (US)
Pages (from-to)394-404
Number of pages11
JournalTrends in Pharmacological Sciences
Issue number7
StatePublished - Jul 2012

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Liver X receptor biology and pharmacology: New pathways, challenges and opportunities'. Together they form a unique fingerprint.

Cite this